Dr. Gupta on the role of immunotherapy as future standard of care for MIBC

Video

“I think the audience would be encouraged to know that in the future, it seems like immunotherapy would become the standard of care,” says Shilpa Gupta, MD.

In this video, Shilpa Gupta, MD, discusses the future research and takeaways associated with the study, “Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Gupta is the director of genitourinary oncology at Cleveland Clinic in Ohio.

Related Videos
Heather L. Huelster, MD, answers a question during a Zoom video interview
3d rendered illustration of kidney cancer | Image Credit: © SciePro - stock.adobe.com
Human kidney cross section on science background | Image Credit: © Crystal light - stock.adobe.com
Illustration of kidney stones | Image Credit: © freshidea - stock.adobe.com
Smita De, MD, PhD, answers a question during a Zoom video interview
Smita De, MD, PhD, answers a question during a Zoom video interview
Close-up of elderly woman about to take aspirin | Image Credit: ©  fizkes - stock.adobe.com
Scott T. Tagawa, MD, MS, FACP, FASCO, an expert on bladder cancer
Scott T. Tagawa, MD, MS, FACP, FASCO, an expert on bladder cancer
Related Content
© 2023 MJH Life Sciences

All rights reserved.